QQQ   346.82 (-0.90%)
AAPL   178.61 (+0.74%)
MSFT   328.09 (-0.94%)
META   261.38 (-0.43%)
GOOGL   122.95 (-0.58%)
AMZN   119.28 (-1.96%)
TSLA   196.60 (-2.27%)
NVDA   381.93 (-4.78%)
NIO   7.36 (-0.67%)
BABA   78.64 (-0.04%)
AMD   118.97 (-5.03%)
T   15.85 (+1.34%)
F   12.02 (-4.53%)
MU   68.24 (-4.81%)
CGC   0.81 (-5.21%)
GE   100.52 (-1.84%)
DIS   87.58 (-0.27%)
AMC   4.41 (-4.75%)
PFE   37.58 (+1.54%)
PYPL   61.44 (-0.98%)
NFLX   391.35 (-0.41%)
QQQ   346.82 (-0.90%)
AAPL   178.61 (+0.74%)
MSFT   328.09 (-0.94%)
META   261.38 (-0.43%)
GOOGL   122.95 (-0.58%)
AMZN   119.28 (-1.96%)
TSLA   196.60 (-2.27%)
NVDA   381.93 (-4.78%)
NIO   7.36 (-0.67%)
BABA   78.64 (-0.04%)
AMD   118.97 (-5.03%)
T   15.85 (+1.34%)
F   12.02 (-4.53%)
MU   68.24 (-4.81%)
CGC   0.81 (-5.21%)
GE   100.52 (-1.84%)
DIS   87.58 (-0.27%)
AMC   4.41 (-4.75%)
PFE   37.58 (+1.54%)
PYPL   61.44 (-0.98%)
NFLX   391.35 (-0.41%)
QQQ   346.82 (-0.90%)
AAPL   178.61 (+0.74%)
MSFT   328.09 (-0.94%)
META   261.38 (-0.43%)
GOOGL   122.95 (-0.58%)
AMZN   119.28 (-1.96%)
TSLA   196.60 (-2.27%)
NVDA   381.93 (-4.78%)
NIO   7.36 (-0.67%)
BABA   78.64 (-0.04%)
AMD   118.97 (-5.03%)
T   15.85 (+1.34%)
F   12.02 (-4.53%)
MU   68.24 (-4.81%)
CGC   0.81 (-5.21%)
GE   100.52 (-1.84%)
DIS   87.58 (-0.27%)
AMC   4.41 (-4.75%)
PFE   37.58 (+1.54%)
PYPL   61.44 (-0.98%)
NFLX   391.35 (-0.41%)
QQQ   346.82 (-0.90%)
AAPL   178.61 (+0.74%)
MSFT   328.09 (-0.94%)
META   261.38 (-0.43%)
GOOGL   122.95 (-0.58%)
AMZN   119.28 (-1.96%)
TSLA   196.60 (-2.27%)
NVDA   381.93 (-4.78%)
NIO   7.36 (-0.67%)
BABA   78.64 (-0.04%)
AMD   118.97 (-5.03%)
T   15.85 (+1.34%)
F   12.02 (-4.53%)
MU   68.24 (-4.81%)
CGC   0.81 (-5.21%)
GE   100.52 (-1.84%)
DIS   87.58 (-0.27%)
AMC   4.41 (-4.75%)
PFE   37.58 (+1.54%)
PYPL   61.44 (-0.98%)
NFLX   391.35 (-0.41%)
NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Forecast, Price & News

$1.95
+0.02 (+1.04%)
(As of 12:52 PM ET)
Compare
Today's Range
$1.89
▼
$2.01
50-Day Range
$0.80
▼
$2.20
52-Week Range
$0.65
▼
$2.41
Volume
1.29 million shs
Average Volume
2.13 million shs
Market Capitalization
$238.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

X4 Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
75.0% Upside
$3.50 Price Target
Short Interest
Healthy
2.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.76mentions of X4 Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.63) to ($0.47) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

197th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

28th out of 167 stocks

See Top Rated MarketRank™ Stocks Here

XFOR stock logo

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

May 25, 2023 | markets.businessinsider.com
Stifel Nicolaus Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)
May 24, 2023 | americanbankingnews.com
FY2023 EPS Estimates for X4 Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:XFOR)
May 31, 2023 | Edge On The Street (Ad)
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
May 23, 2023 | americanbankingnews.com
B. Riley Analysts Raise Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)
May 20, 2023 | americanbankingnews.com
Stifel Nicolaus Boosts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $5.00
May 20, 2023 | americanbankingnews.com
FY2026 EPS Estimates for X4 Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:XFOR)
May 19, 2023 | americanbankingnews.com
Brookline Capital Management Analysts Raise Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)
May 17, 2023 | msn.com
Stifel Maintains X4 Pharmaceuticals (XFOR) Buy Recommendation
May 31, 2023 | Edge On The Street (Ad)
AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
May 17, 2023 | msn.com
Unusual Call Option Trade in X4 Pharmaceuticals (XFOR) Worth $24.36K
May 17, 2023 | msn.com
X4 Pharma Highlights 'Significant Reduction' Rate In Severity, Duration Of Infections
May 16, 2023 | finance.yahoo.com
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
May 16, 2023 | finance.yahoo.com
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
May 10, 2023 | americanbankingnews.com
Analysts Set Expectations for X4 Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:XFOR)
May 6, 2023 | americanbankingnews.com
Opthea (NASDAQ:OPT) versus X4 Pharmaceuticals (NASDAQ:XFOR) Critical Contrast
May 5, 2023 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About X4 Pharmaceuticals
May 5, 2023 | msn.com
HC Wainwright & Co. Reiterates X4 Pharmaceuticals (XFOR) Buy Recommendation
May 4, 2023 | msn.com
X4 Pharmaceuticals: Q1 Earnings Insights
May 4, 2023 | finance.yahoo.com
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
April 29, 2023 | americanbankingnews.com
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 86.8% in April
April 26, 2023 | finance.yahoo.com
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
April 26, 2023 | finance.yahoo.com
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are retail investors with 42% ownership, institutions own 32%
April 12, 2023 | finance.yahoo.com
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
April 12, 2023 | americanbankingnews.com
X4 Pharmaceuticals (NASDAQ:XFOR) Given New $3.00 Price Target at B. Riley
April 10, 2023 | msn.com
B. Riley Securities Maintains X4 Pharmaceuticals (XFOR) Buy Recommendation
April 6, 2023 | markets.businessinsider.com
B.Riley Financial Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)
April 4, 2023 | finance.yahoo.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
See More Headlines
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Company Calendar

Last Earnings
3/21/2023
Today
5/31/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XFOR
CUSIP
N/A
CIK
1501697
Web
www.x4pharma.com
Phone
(857) 529-8300
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+81.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-93,870,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-176.29%
Return on Assets
-80.88%

Debt

Debt-to-Equity Ratio
0.62
Current Ratio
5.04
Quick Ratio
5.04

Sales & Book Value

Annual Sales
$3 million
Price / Sales
78.62
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
3.16

Miscellaneous

Outstanding Shares
122,207,000
Free Float
120,887,000
Market Cap
$235.86 million
Optionable
Not Optionable
Beta
0.70

Key Executives

  • Paula S. RaganPaula S. Ragan
    President, Chief Executive Officer & Director
  • Mary DiBiase
    Chief Operating Officer
  • Adam S. MostafaAdam S. Mostafa
    Chief Financial Officer & Treasurer
  • Murray Willis Stewart
    Independent Director & Chief Medical Officer
  • Art Taveras
    Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













XFOR Stock - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XFOR shares.
View XFOR analyst ratings or view top-rated stocks.

What is X4 Pharmaceuticals' stock price forecast for 2023?

5 analysts have issued twelve-month target prices for X4 Pharmaceuticals' shares. Their XFOR share price forecasts range from $3.00 to $5.00. On average, they expect the company's share price to reach $3.50 in the next year. This suggests a possible upside of 81.3% from the stock's current price.
View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts.

How have XFOR shares performed in 2023?

X4 Pharmaceuticals' stock was trading at $0.9930 on January 1st, 2023. Since then, XFOR shares have increased by 94.4% and is now trading at $1.93.
View the best growth stocks for 2023 here.

When is X4 Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our XFOR earnings forecast.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its earnings results on Tuesday, March, 21st. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.06.

What ETFs hold X4 Pharmaceuticals' stock?

ETFs with the largest weight of X4 Pharmaceuticals (NASDAQ:XFOR) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and Simplify Propel Opportunities ETF (SURI) and

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (3.72%), AXA S.A. (3.60%), Geode Capital Management LLC (0.91%), Schonfeld Strategic Advisors LLC (0.85%), Ghost Tree Capital LLC (0.70%) and JPMorgan Chase & Co. (0.51%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Arthur Taveras, Derek M Meisner, Derek M Meisner, Mary Dibiase, Paula Ragan and Renato Skerlj.
View institutional ownership trends.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $1.93.

How much money does X4 Pharmaceuticals make?

X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $235.86 million and generates $3 million in revenue each year. The company earns $-93,870,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com.

This page (NASDAQ:XFOR) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -